NCT03760549View on ClinicalTrials.gov

Study of the Safety and Immunogenicity of NasoVAX Extension

CompletedOBSERVATIONAL

Enrollment

8

Participants

Timeline

Start Date

January 21, 2019

Primary Completion Date

February 18, 2019

Study Completion Date

February 18, 2019

Conditions

Influenza

Interventions

DRUG

Subjects were administered NasoVAX high dose

NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo

Trial Locations (1)

20850

Optimal Health Research, Rockville

Sponsors

Lead Sponsor

Altimmune, Inc.

All Listed Sponsors

lead

Altimmune, Inc.

INDUSTRY

NCT03760549 - Study of the Safety and Immunogenicity of NasoVAX Extension | Biotech Hunter | Biotech Hunter